T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
|Videos|October 14, 2019
Dr. William Wood on the Clinical Risk of Chemo in Early Breast Cancer
Author(s)William Wood, MD
CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer.
Advertisement
CancerNetwork® spoke with Dr. William Wood, professor of medicine at Emory University in Atlanta, Georgia, about the clinical risk of chemotherapy in early breast cancer.
Advertisement
Related to this article
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.
Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.
Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
5